Litigation Details for CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC. (D.N.J. 2018)
✉ Email this page to a colleague
CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC. (D.N.J. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-06-19 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-05-13 |
| Cause | 15:1126 Patent Infringement | Assigned To | Esther Salas |
| Jury Demand | None | Referred To | Michael A. Hammer |
| Parties | SYNTHON B.V. | ||
| Patents | 6,281,230; 6,476,052; 6,555,554; 7,393,862; 7,968,569; 8,198,262; 8,673,939; 8,735,428; 8,828,427; 9,993,467 | ||
| Attorneys | AARON SCOTT ECKENTHAL | ||
| Firms | Saul Ewing Arnstein & Lehr LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Biologic Drugs cited in CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for CELGENE CORPORATION v. SYNTHON PHARMECEUTICALS, INC. (D.N.J. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-06-19 | 1 | Complaint | Corporation, Summit, NJ (US) 6,281,230 B1 8/2001 Muller eta!. … a patient in need of such treatment or pre- 6,281,230 and 6,316,471, both to G. W. Muller, eta!. … such as those described in U.S. Pat. Nos. 6,281,230 and proteins and antibodies), examples of which… Pat. Nos. 6,281,230; 6,316,471; 6,335,349; and 6,476,052, compounds…antibiotics, collagen, botulinum toxin, inter- Nos. 6,281,230 and 5,635,517; U.S. publication nos. 2004/ | External link to document |
| 2018-11-19 | 24 | Amended Complaint | Corporation, Summit, NJ (US) 6,281,230 B1 8/2001 Muller eta!. …a patient in need of such treatment or pre- 6,281,230 and 6,316,471, both to G. W. Muller, eta!. … such as those described in U.S. Pat. Nos. 6,281,230 and proteins and antibodies), examples of which… Pat. Nos. 6,281,230; 6,316,471; 6,335,349; and 6,476,052, compounds…antibiotics, collagen, botulinum toxin, inter- Nos. 6,281,230 and 5,635,517; U.S. publication nos. 2004/ | External link to document |
| 2019-05-09 | 50 | Letter | Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 8,198,262; 8,673,939; 8,735,428; … 4. Until expiration of the Patents-in-Suit, Synthon, including any of its successors…successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third …parties in connection with any infringement of the Patents-in-Suit by any such third parties in connection… 21 C.F.R. § 314.94(a)(12) with respect to the Patents-in-Suit. 9. Nothing herein | External link to document |
| 2019-05-13 | 52 | Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 8.198,262; 8,673,939; 8.735.428: …10,093,648: and 10,093,649, 4. Until expiration of the Patents-in-Suit. Synthon, including any of its successors…successors and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third party…parties in connection with any infringement of the Patents-in-Suit by any such third parties in connection…21 C.F.R. §$ 314.94(a)(12) with respect to the Patents-in-Suit. 9, Nothing herein restricts or is intended | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
